Biogen reports a positive balance in 2023 with $9.8 billion in revenues, a 3% decrease. Q4 2023 sales were $2.4 billion, down 6% from the same...
The US biotech group Biogen dares to make a new start with its Alzheimer's drug Aducanumab, the group plans to submit an application for approval in...
Many people may know someone who has suffered or continues to suffer from diseases like cancer which has no proven cure. Scientists are still finding ways...
The Second Wave Cycle shows you where you can gain the most profit while others are looking away.